Nucleic Acid Therapeutics Market Forecast Reveals Where Future Industry Value Will Be Created
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Nucleic Acid Therapeutics Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for nucleic acid therapeutics has seen substantial recent expansion. Projected to rise from $6.94 billion in 2025 to $8.01 billion in 2026, this reflects a compound annual growth rate (CAGR) of 15.4%. This historical growth is driven by factors such as the constrained supply of these therapeutics, a continued dependence on conventional small-molecule treatments, an escalating need for precision medicine, regulatory clearances granted for initial gene therapies, and a surge in academic investigations into gene modulation.
The predicted trajectory for the nucleic acid therapeutics market indicates robust expansion over the coming years. By 2030, the sector is projected to reach a valuation of $14.07 billion, driven by a compound annual growth rate (CAGR) of 15.1%. This forecasted upswing is fueled by key developments such as the advancement of CRISPR and other gene-editing tools, the broader implementation of lipid nanoparticle (LNP) delivery platforms, a growing preference for customized nucleic acid treatments, heightened collaborative efforts between pharmaceutical firms and biotechnology companies, and increased funding directed toward RNA-based therapies. Among the prominent trends shaping this period are the growing utilization of antisense oligonucleotides (ASOs) and siRNA therapies, the broadening application of CRISPR-based and gene-editing treatments, a surge in precision therapies targeting neuromuscular, metabolic, and oncological conditions, intensified investment in both non-viral and viral delivery mechanisms, and the nascent rise of long non-coding RNA (lncRNA) and microRNA (miRNA) therapeutic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Nucleic Acid Therapeutics Market Expansion Supported By Key Demand Factors
An anticipated expansion in the nucleic acid therapeutics market is being driven by the rising prevalence of genetic and chronic diseases. These conditions involve the connection between hereditary genetic influences and the emergence, advancement, or heightened risk of enduring health issues like diabetes, cardiovascular ailments, cancer, and autoimmune disorders. The growing occurrence of such diseases is mainly fueled by enhanced diagnostic tools that enable earlier and more precise detection. Nucleic acid therapeutics prove effective against these disorders because they can directly address the underlying genetic causes by regulating, repairing, or silencing specific genes, thus providing tailored and exact treatment approaches. An example is found in October 2024, when the Cystic Fibrosis Trust, a UK charity focused on assisting those with cystic fibrosis, reported 11,148 registered patients in 2022, which rose to 11,318 in 2023—a 1.5% annual increase in patient numbers. Consequently, the escalating incidence of genetic and chronic conditions is propelling the expansion of the nucleic acid therapeutics market.
Nucleic Acid Therapeutics Market Categorization By Product Type And Application
The nucleic acid therapeutics market covered in this report is segmented –
1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas
3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies
Subsegments:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA
3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs
4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers
5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes
Nucleic Acid Therapeutics Market Growth Trends Influencing Competitive Dynamics
Top firms in the nucleic acid therapeutics space are concentrating on advancing cutting-edge treatments like antisense oligonucleotide therapy, engineered to target and silence specific genes responsible for diseases, thus delivering precise therapeutic options for genetic disorders and rare conditions. This approach employs short, synthetic DNA or RNA strands to inhibit or alter the expression of particular genes linked to illness. A key example occurred in December 2024 when Ionis Pharmaceuticals Inc., a biotechnology company based in the United States, secured approval from the FDA for TRYNGOLZ (olezarsen). Used as an addition to dietary measures, it lowers triglyceride levels in adults with familial chylomicronemia syndrome (FCS), a rare genetic condition marked by severe hypertriglyceridemia (sHTG) and a heightened acute pancreatitis (AP) risk. This therapy is the first FDA-endorsed option to achieve substantial and sustained triglyceride reduction in these patients, while also notably decreasing AP occurrence when paired with a low-fat diet. Additionally, it enables convenient monthly self-administration via an auto-injector.
Nucleic Acid Therapeutics Market Company Landscape And Strategic Competition
Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.
Access The Complete Nucleic Acid Therapeutics Market Report:
Nucleic Acid Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
